New Drug Reviews

Levomilnacipran (Fetzima) for Major Depressive Disorder


Am Fam Physician. 2015 Oct 15;92(8):727-731.

Levomilnacipran (Fetzima) is a serotonin-norepinephrine reuptake inhibitor (SNRI) labeled for the treatment of major depressive disorder in adults.1

 Enlarge     Print

DrugDosageDose formCost*

Levomilnacipran (Fetzima)

20 mg per day for two days, then increases to 40 mg per day (maximum = 120 mg per day)

20-, 40-, 80-, and 120-mg capsules

$286 for 30 capsules (prices are identical for 20-,40-, 80-, and 120-mg capsules)

*—Estimated retail price of one month's treatment based on information obtained at (accessed August 19, 2015).

DrugDosageDose formCost*

Levomilnacipran (Fetzima)

20 mg per day for two days, then increases to 40 mg per day (maximum = 120 mg per day)

20-, 40-, 80-, and 120-mg capsules

$286 for 30 capsules (prices are identical for 20-,40-, 80-, and 120-mg capsules)

*—Estimated retail price of one month's treatment based on information obtained at (accessed August 19, 2015).


Levomilnacipran causes few serious adverse effects, although long-term safety has not been established.2 As with all antidepressants, levomilnacipran carries a warning of increased risk of suicidal thoughts and behavior in patients 24 years or younger, and it has not been studied in patients younger than 18 years.1 Levomilnacipran increases systolic and diastolic blood pressure by a median of 4 mm Hg and 2.5 mm Hg, respectively,2 and 3% of patients (95% confidence interval, 1% to 6%) with normal blood pressure or prehypertension will develop hypertension.3 The manufacturer recommends against using it in patients with poorly controlled hypertension.1 Blood pressure should be routinely measured until the effect of levomilnacipran is determined. It does not cause clinically significant changes in basic laboratory tests or QT prolongation.2,46 Patients should avoid using levomilnacipran with serotonergic drugs, such as monoamine oxidase inhibitors, triptans, tramadol, and other antidepressants to minimize the risk of serotonin syndrome.1 The dosage of levomilnacipran should be limited to 80 mg per day when used concurrently with a cytochrome P450 3A4 inhibitor because levomilnacipran is partially metabolized by the liver, and medications that inhibit the cytochrome P450 3A4 system, such as ketoconazole, may cause it to accumulate.1 Patients with moderate and severe renal impairment should be limited to a dosage of 80 mg per day and 40 mg per day, respectively. 1


About one in six patients will experience nausea, and about one in 11 patients will experience hyperhydrosis. Other adverse effects include headache, tachycardia, palpitations, constipation, and erectile dysfunction and ejaculation disorder in men.2,47 Levomilnacipran does not cause weight gain.2,4,5,7 Adverse effects lead to discontinuation of treatment in approximately 8.8% of patients by eight weeks and 13% of patients by one year.2,3


The effect of levomilnacipran on mild to moderate major depression has not been studied. In outpatients with moderate to severe depression, about one in four patients (27.8%) will achieve remission (a score of less than 10 on the Montgomery-Åsberg Depression Rating Scale [MADRS]).37 Levomilnacipran induced a treatment response (i.e., more than 50% reduction in the MADRS score) in 44.8% of patients.37 Short-term research has not demonstrated an effect of levomilnacipran on relapse rates.8 There is no research comparing levomilnacipran with other antidepressants.


A one-month supply of levomilnacipran costs approximately $286. Prices are identical for 20-, 40-, 80-, and 120-mg capsules. In comparison, a 30-day supply of venlafaxine (37.5 mg per day) costs approximately $15, and duloxetine (Cymbalta; 30 mg per day) costs approximately $40.


Levomilnacipran should be taken once daily at the same time of day, with or without food. The starting dosage is 20 mg per day for two days, then increases to 40 mg per day. Based on tolerability and effectiveness, the dosage may be titrated upward by 40 mg every two days to a maximum dosage of 120 mg per day.1 Typical target dosages in flexible-dose clinical studies ranged from 80 mg per day to 120 mg per day.5,6

Bottom Line

Levomilnacipran should not be used in patients with mild to moderate depression until studies have proven its effectiveness. It is somewhat effective in patients with moderate to severe depression. The short-term adverse effect profile of levomilnacipran is similar to that of other SNRIs. However, there is no research comparing it with other antidepressants, and it lacks long-term safety data. Levomilnacipran is also considerably more expensive than other antidepressants.

Address correspondence to Samira Zaman, MD, at Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.


show all references

1. Fetzima (levomilnacipran hydrochloride capsule, extended release). DailyMed. Bethesda, Md.: U.S. National Library of Medicine. Updated July 2014. Accessed January 21, 2015....

2. Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study [published correction appears in Clin Drug Investig. 2013;33(11):861]. Clin Drug Investig. 2013;33(10):761–771.

3. Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67(11):1089–1104.

4. Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39(1):40–49.

5. Sambunaris A, Bose A, Gommoll CP, Chen C, Green-berg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(1):47–56.

6. Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013;74(4):363–369.

7. Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(3):242–248.

8. Shiovitz T, Greenberg WM, Chen C, Forero G, Gommoll CP. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder. Innov Clin Neurosci. 2014;11(1–2):10–22.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Contributing Editor.

A collection of STEPS published in AFP is available at



Copyright © 2015 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article